☆ 4.8 Review

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Lung cancer and oncolytic virotherapy--enemy's enemy

Zhang Li et al.

Summary: Lung cancer and the covid-19 virus are both significant threats to human health. Oncolytic virotherapy, a strategy that uses viruses to combat cancer cells, shows promise in selective tumor cell killing and induction of systemic anti-tumor immunity for lung cancer treatment. However, further research and development are needed before it becomes a standard treatment.

TRANSLATIONAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC

Mehrdad Rakaee et al.

Summary: This study developed a machine-learning-based approach to evaluate the association between tumor-infiltrating lymphocytes (TILs) and immune checkpoint inhibitor (ICI) therapy in lung cancer patients. The results showed that high levels of TILs were associated with ICI treatment response and could be used for patient selection and precision therapy guidance.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

Lee X. Li et al.

Summary: This study evaluated the risk of hyperprogression with the use of immune checkpoint inhibitor (ICI) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer (NSCLC) and provided insights into hyperprogression risk with contemporary first-line ICI treatment.

ONCOLOGIST (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy*

Weifeng Zhang et al.

Summary: The study reveals that GSH and IgG4 in the tumor microenvironment can synergistically inhibit immune responses and promote tumor growth. This effect is achieved through the Fc-Fc reaction between IgG4 and other tissue-bound IgG subtypes, which is facilitated by GSH disrupting the disulfide bonds of IgG4. This finding provides a new understanding of the interaction between the redox system and the immune system in the tumor microenvironment and has implications for cancer immunotherapy.

REDOX BIOLOGY (2023)

Add to Collection

Article Oncology

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Gaopeng Li et al.

Summary: Immune checkpoint blockade can have durable responses against cancer, but some patients experience rapid cancer progression during immunotherapy. The mechanism behind how tumors accelerate their progression during immune checkpoint blockade is not well understood. In preclinical models, immune checkpoint blockade can cause hyperprogressive disease. Interestingly, patients with hyperprogressive disease but not complete response exhibit elevated levels of tumor fibroblast growth factor 2 and β-catenin signaling. T cell-derived interferon γ promotes tumor fibroblast growth factor 2 signaling, suppressing PKM2 activity and decreasing NAD+ levels, which leads to enhanced β-catenin acetylation and reprogramming of tumor stemness. Targeting the interferon γ-PKM2-β-catenin axis can prevent hyperprogressive disease in preclinical models. These findings demonstrate the importance of the crosstalk between immunogenic, metabolic, and oncogenic pathways in immune checkpoint blockade-associated hyperprogressive disease.

CANCER CELL (2023)

Add to Collection

Review Immunology

The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice

Joseph Zouein et al.

Summary: Lung cancer, the second most common cancer worldwide, can benefit from immunotherapy as a first-line treatment option, but acquired resistance to immune checkpoint inhibitors can still occur. Chemotherapy can enhance tumor response to immunotherapy. The FDA approvals for using a combination of ICIs and chemotherapy in managing metastatic non-small-cell lung cancer are summarized.

IMMUNOTHERAPY (2022)

Add to Collection

Review Immunology

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

Carlo Genova et al.

Summary: The tumor microenvironment (TME) plays a crucial role in mediating the response to immunotherapy in non-small cell lung cancer (NSCLC). Modulating the TME towards an immunogenic state shows promise in enhancing the activity of immune checkpoint inhibitors (ICI). Clinical trials targeting TME components and investigating novel therapeutic targets are underway to improve the outcomes of cancer immunotherapy.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients

Marc-Andre Leger et al.

Summary: This article discusses the importance of strategies in clinical management of lung cancer patients over the past decade, particularly focusing on immunotherapy. It emphasizes the creation of novel standardized response criteria and the use of FDG PET/CT metrics to predict response to ICI therapy. Additionally, it mentions the potential immune-related adverse events associated with ICI therapy.

SEMINARS IN NUCLEAR MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma

Zhimin Zeng et al.

Summary: A six-IRL signature was identified in LUAD, stratifying patients into high- and low-risk groups. The low-risk group showed improved survival outcomes, a stronger response to ICI, higher expression levels of immune checkpoint molecules, but also expressed more biomarkers of hyperprogressive disease in immunotherapy.

DIAGNOSTICS (2022)

Add to Collection

Article Oncology

Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment

Jehun Kim et al.

Summary: This study aimed to investigate the clinical characteristics, outcomes, and associated factors of hyperprogressive disease (HPD) in patients with non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (ICI) therapy using a semiautomatic volume measurement. The study found that patients with HPD had shorter progression-free survival (PFS) compared to patients without HPD, and factors such as PD-L1 expression, number of metastatic sites, neutrophil-to-lymphocyte ratio, and hemoglobin level were associated with HPD.

THORACIC CANCER (2022)

Add to Collection

Article Oncology

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

Elisabetta Zulato et al.

Summary: This study characterized patients with hyperprogression (HPD) and early death (ED) in advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitors (ICIs) through longitudinal liquid biopsy. The quantification of cfDNA and variant allele fraction (VAF) of tumor-associated genetic alterations were evaluated for their impact on outcome. The study proposed a two-step risk assessment model based on optimal cutoff values. Early liquid biopsy has the potential to identify high-risk patients for ED and HPD.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy

Mengxiao Wang et al.

Summary: This study found that considering multiple new lesions in the definition of hyperprogressive disease (HPD) has a better prognostic value. The presence of new lesions was associated with a shorter overall survival in PD (with or without HPD) patients.

LUNG CANCER (2022)

Add to Collection

Article Oncology

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy

Hiroaki Wakiyama et al.

Summary: This study demonstrates the use of NIR-PIT to deplete CD8(+) T cells and temporarily change the balance of T-cell subsets in the tumor microenvironment, leading to rapid tumor progression after PD-1 blockade therapy. The results suggest that imbalances between effector T cells and regulatory T cells in the tumor microenvironment may contribute to hyperprogressive disease following PD-1 blockade therapy.

CANCER IMMUNOLOGY RESEARCH (2022)

Add to Collection

Article Oncology

The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

Seo Ree Kim et al.

Summary: This study found that in NSCLC patients receiving immunotherapy, HPD was significantly associated with heavy smoking, low PD-L1 expression, multiple metastases, lower CD8+/PD-1+ TIL, and more M2 macrophages in the tumor microenvironment.

BMC CANCER (2021)

Add to Collection

Article Oncology

Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy

Norikazu Matsuo et al.

Summary: A retrospective study of lung cancer patients found that the incidence of immune-related adverse events and hyperprogressive disease within 3 months after treatment initiation was lower in patients receiving PD-1/PD-L1 inhibitors in combination with chemotherapy, especially in terms of pneumonitis. Further research is needed to investigate the mechanisms underlying these differences.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Immunology

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer

Bo Mi Ku et al.

Summary: This study evaluated the predictive and prognostic effects of various immune cells in pretreatment tissue samples of NSCLC patients treated with PD-1 blockade, finding that T cells were the most dominant immune cell type. High T-cell, B-cell, and macrophage density in the tumor/stroma region was associated with durable clinical benefit. Additionally, high intratumoral B-cell density was shown to have an impact on overall survival, while hyperprogressive disease was significantly associated with intratumoral B-cell density.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors

B. Abbar et al.

Summary: This study retrospectively analyzed medical records of lung cancer patients treated with ICI from 2015 to 2018, finding heterogeneous rates of hyperprogression depending on the definition used. Only the definition of time to treatment failure was significantly associated with worsened overall survival. Further studies are needed to establish consensus recommendations for the assessment, definition, and management of hyperprogression.

LUNG CANCER (2021)

Add to Collection

Review Medicine, Research & Experimental

Traditional Chinese medicine and lung cancer-From theory to practice

Zhang Li et al.

Summary: With continuous breakthroughs in molecular biology and biochemistry, significant progress has been made in the treatment of lung cancer, particularly with standard treatments improving patient prognosis and immunotherapy providing positive outcomes. In contrast, traditional Chinese medicine has limited research in the field of lung cancer, but has shown progress in non-small cell lung cancer.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Add to Collection

Article Oncology

Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach

Chorog Song et al.

Summary: After ICI treatment, unique responses such as hyperprogressive disease (HPD) and a dissociated response (DR) have been reported, which are difficult to evaluate using conventional methods. This study aimed to evaluate radiomics features of HPD at the lesion level and understand the clinical significance of a dissociated response. Organ-specific radiomics features were identified to discriminate HPD, and a dissociated response was found to be associated with poor overall survival. The radiomic lesion-level approach shows great potential for response evaluation of ICI treatment.

CANCERS (2021)

Add to Collection

Article Oncology

Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers

Kristin L. Ayers et al.

Summary: Analysis of real-world data showed longer time-to-treatment discontinuation and overall survival in African American patients with aNSCLC treated with anti-PD-1/PD-L1 inhibitors. Lower incidence of putative hyperprogressive diseases may contribute to the favorable outcomes in this patient population.

ONCOLOGIST (2021)

Add to Collection

Review Medicine, General & Internal

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis

Hyo Jung Park et al.

Summary: HPD is a recognized pattern of rapid tumor progression during immune checkpoint inhibitor treatment. The incidence of HPD varies from 5.9% to 43.1% across studies examined. Definitions of HPD are diverse, indicating the need for establishing uniform criteria based on currently available evidence.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Oncology

Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report

Y. O. S. U. K. E. SHIONOYA et al.

Summary: ICIs, including nivolumab and pembrolizumab, have shown clinical benefits in advanced NSCLC patients, but distinguishing pseudo-PD from HPD remains challenging.

ANTICANCER RESEARCH (2021)

Add to Collection

Letter Oncology

Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer

Kosuke Hashimoto et al.

LUNG CANCER (2020)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET/CT

Angelo Castello et al.

JOURNAL OF NUCLEAR MEDICINE (2020)

Add to Collection

Review Oncology

Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature

Miruna Grecea et al.

ONCOLOGIST (2020)

Add to Collection

Article Oncology

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

Hugo Arasanz et al.

CANCERS (2020)

Add to Collection

Review Oncology

Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer

Giuseppe Lo Russo et al.

CURRENT ONCOLOGY REPORTS (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

Xueping Wang et al.

MOLECULAR CANCER (2020)

Add to Collection

Article Immunology

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer

M. P. Petrova et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis

Yan Chen et al.

BMC CANCER (2020)

Add to Collection

Article Oncology

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer

Baptiste Kas et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease

Soo Han Kim et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors

Yong Jun Choi et al.

THORACIC CANCER (2020)

Add to Collection

Review Oncology

Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature

Laiyan Zhou et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade

Pranjal Vaidya et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC

Yao Chen et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Review Immunology

Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Jung-Ho Kim et al.

IMMUNE NETWORK (2020)

Add to Collection

Article Oncology

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

Giuseppe Lo Russo et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report

Ilke Tunali et al.

LUNG CANCER (2019)

Add to Collection

Article Oncology

Durvalumab-Induced Hyperprogressive Disease in Nonmetastatic Lung Cancer

Tariq J. Khreis et al.

JOURNAL OF ONCOLOGY PRACTICE (2019)

Add to Collection

Article Oncology

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

C. G. Kim et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Nivolumab-refractory patients with advanced non-small-cell lung cancer

A. Costantini et al.

LUNG CANCER (2019)

Add to Collection

Article Multidisciplinary Sciences

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

Takahiro Kamada et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection

Review Oncology

Are we ready to describe response or progression to immunotherapy in lung cancer?

Giorgia Guaitoli et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)

Add to Collection

Article Oncology

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Youjin Kim et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Letter Oncology

Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification

Xiu Huang et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy

Komugi Okeya et al.

INTERNAL MEDICINE (2019)

Add to Collection

Article Medicine, Research & Experimental

Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer

Chihiro Ando et al.

IN VIVO (2019)

Add to Collection

Article Respiratory System

Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis

Deirdre M. H. J. ten Berge et al.

ERJ OPEN RESEARCH (2019)

Add to Collection

Article Respiratory System

Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study

Yuko Tanaka et al.

RESPIRATORY MEDICINE CASE REPORTS (2019)

Add to Collection

Article Medicine, General & Internal

A Case Report of the Clinico-radiologic Challenges of Assessing Treatment Response after Stereotactic Radiation of Oligometastases Preceded by Immunotherapy: Pseudoprogression, Mixed Response Patterns, and Opportunities for Precision Radiation

Arif S. Rashid et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2019)

Add to Collection

Review Respiratory System

Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy

Jonathan S. Kurman et al.

JOURNAL OF THORACIC DISEASE (2018)

Add to Collection

Article Oncology

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Laura Mezquita et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Oncology

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara et al.

JAMA ONCOLOGY (2018)

Add to Collection

Review Oncology

Hyperprogressive disease: recognizing a novel pattern to improve patient management

Stephane Champiat et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series

Masaki Kanazu et al.

THORACIC CANCER (2018)

Add to Collection

Article Oncology

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stephane Champiat et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Review Oncology

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Lesley Seymour et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

Shumei Kato et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

© Peeref 2019-2024. All rights reserved.